Stryker, Johnson & Johnson and Zimmer Biomet posted their fourth-quarter and full-year financial results for 2025, along with data on their spine orthopedic sales.
Here is how they compare:
2025 sales: $25.1 billion (+11.2%)
2025 Orthopedics: $9.5 billion (+4.3%)
2025 Hips: $1.9 billion (+9.5%)
2025 Knees: $2.7 billion (+8.5%)
2025 Spine: $185 million
Q4 sales: $7.2 billion (+11.4%)
2025 sales: $8.2 billion (+7.2%)
2025 Hips: $2 million (+4.7%)
2025 Knees: $3.2 billion (+4.7%)
2025 Sports medicine, extremities, trauma, craniomaxillofacial and thoracic: $2.1 billion (+15.2%)
Q4 sales: $2.24 billion
2025 Medtech sales: $94.2 billion (+6%)
2025 Orthopedic: $9.2 billion (+1.1%)
2025 Spine, sports and other: $2.8 billion (-2.5%)
2025 Hips: $1.67 billion (+2.1%)
2025 Knees: $1.58 billion (+2.7%)
Q4 sales: $24.6 billion (+9.1%)
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
